Please Wait.....
Report
Global Autologous Cell Therapy Market Report and Forecast 2024-2032
Market Report I 2023-10-01 I 140 Pages I EMR Inc.
Global Autologous Cell Therapy Market Report and Forecast 2024-2032
Global Autologous Cell Therapy Market Outlook
The global autologous cell therapy market size was valued at USD 7.8 billion in 2023, driven by the increasing prevalence of chronic diseases, cancer, and a growing focus on personalized medicine across the globe. The market size is anticipated to grow at a CAGR of 19.4% during the forecast period of 2024-2032 to achieve a value of USD 38.4 billion by 2032.
Autologous Cell Therapy: Introduction
Autologous cell therapy represents a cutting-edge and personalized approach in the field of regenerative medicine and treatment of various diseases. This therapeutic method involves harvesting cells from a patient's own body, manipulating or culturing them in a controlled environment, and then reintroducing them into the patient's body to achieve a therapeutic effect. The key advantage of autologous cell therapy is the significantly reduced risk of immune rejection, as the cells originate from the patient. This therapy has been explored and applied in a wide range of medical fields, including oncology for cancer treatment, particularly with the advent of CAR-T cell therapies, in regenerative medicine for repairing damaged tissues, and in the treatment of autoimmune diseases.
Autologous cell therapy represents a leap forward in personalized medicine, offering targeted and individualized treatment options based on a patient's unique cellular makeup, potentially leading to more effective and safer treatments compared to conventional methods.
Key Trends in the Global Autologous Cell Therapy Market
The global autologous cell therapy market was witnessing several key trends shaping its growth and development. Firstly, there was a substantial increase in clinical research and trials, focusing on the potential of autologous cell therapies in treating a wide range of diseases, including various forms of cancer, degenerative diseases, and autoimmune disorders. This was coupled with significant advancements in cell culturing techniques and genetic engineering, leading to more effective and targeted therapies. Personalized medicine was at the forefront, with a growing emphasis on developing treatments tailored to individual patients' genetic and cellular profiles. Regulatory agencies were increasingly recognizing and approving autologous cell therapies, providing a framework for safe and controlled application.
Additionally, there was a trend towards partnerships and collaborations between biotech companies, academic institutions, and healthcare providers, aimed at accelerating research and expanding treatment accessibility. Despite these positive trends, the market faced challenges such as high costs of therapy development and delivery, complex manufacturing processes, and the need for specialized healthcare infrastructure. Nevertheless, these trends were indicative of a dynamic and evolving market, with autologous cell therapy being viewed as a promising frontier in modern medicine.
Global Autologous Cell Therapy Market Segmentation
Market Breakup by Therapy
- Autologous Stem Cell Therapy
- Autologous Cellular Immunotherapies
Market Breakup by Source
- Bone Marrow
- Epidermis
- Others
Market Breakup by Application
- Oncology
- Musculoskeletal Disorder
- Blood Disorder
- Autoimmune Disease
- Others
Market Breakup by End User
- Hospitals
- Research Centres
- Cancer Treatment Centres
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Autologous Cell Therapy Market Overview
The global autologous cell therapy market was a rapidly evolving and promising segment in the field of advanced therapeutics. This market's growth was primarily driven by the increasing prevalence of chronic diseases, cancer, and a growing focus on personalized medicine. North America was a leading market, attributed to its advanced healthcare infrastructure, substantial investments in research and development, and supportive regulatory environment. Europe also held a significant market share, with ongoing clinical trials and growing adoption of innovative therapies. Meanwhile, the Asia Pacific region was emerging as a fast-growing market, driven by rising healthcare spending, increasing prevalence of chronic diseases, and expanding healthcare infrastructure.
The autologous cell therapy market growth was characterized by intense research activities, with numerous clinical trials exploring the efficacy of autologous cell therapies in various medical conditions. Companies in this space were heavily investing in developing new therapies and improving manufacturing processes. Despite the significant potential, the market faced challenges such as high treatment costs, complex manufacturing and logistics, and stringent regulatory requirements. Nonetheless, the global Autologous Cell Therapy market was anticipated to continue its growth trajectory, fueled by the pressing need for more effective and personalized treatment options in healthcare.
Global Autologous Cell Therapy Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Sanpower Group (Dendreon Pharmaceuticals LLC.)
- Holostem Terapie Avanzate S.r.l.
- Novartis AG
- Tego Science
- GC Biopharma (GC Cell)
- Gilead Sciences
- Johnson & Johnson (Janssen Biotech, Inc)
- Bristol Myers Squibb
- CORESTEM, Inc
- Vericel Corporation
- Opexa Therapeutics
- Lineage Cell Therapeutics, Inc.
- Pharmicell Co., Inc.
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Autologous Cell Therapy Market Overview
3.1 Global Autologous Cell Therapy Market Historical Value (2017-2023)
3.2 Global Autologous Cell Therapy Market Forecast Value (2024-2032)
4 Global Autologous Cell Therapy Market Landscape
4.1 Global Autologous Cell Therapy Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Autologous Cell Therapy Product Landscape
4.2.1 Analysis by Therapy
4.2.2 Analysis by Source
4.2.3 Analysis by Application
5 Global Autologous Cell Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Autologous Cell Therapy Market Segmentation
6.1 Global Autologous Cell Therapy Market by Therapy
6.1.1 Market Overview
6.1.2 Autologous Stem Cell Therapy
6.1.3 Autologous Cellular Immunotherapies
6.2 Global Autologous Cell Therapy Market by Source
6.2.1 Market Overview
6.2.2 Bone Marrow
6.2.3 Epidermis
6.2.4 Others
6.3 Global Autologous Cell Therapy Market by Application
6.3.1 Market Overview
6.3.2 Oncology
6.3.3 Musculoskeletal Disorder
6.3.4 Blood Disorder
6.3.5 Autoimmune Disease
6.3.6 Others
6.4 Global Autologous Cell Therapy Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Research Centers
6.4.4 Cancer Treatment Centres
6.4.5 Others
6.5 Global Autologous Cell Therapy Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Autologous Cell Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Autologous Cell Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Autologous Cell Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Autologous Cell Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Autologous Cell Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by Year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding & Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 Sanpower Group (Dendreon Pharmaceuticals LLC.)
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Holostem Terapie Avanzate S.r.l.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Novartis AG
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Tego Science
18.4.1 Financial Analysis
18.4.2 Financial Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 GC Biopharma (GC Cell)
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Gilead Sciences
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Johnson & Johnson (Janssen Biotech, Inc)
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Bristol Myers Squibb
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 CORESTEM, Inc
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Vericel Corporation
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Opexa Therapeutics
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Lineage Cell Therapeutics, Inc.
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Pharmicell Co., Inc.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
19 Global Autologous Cell Therapy Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security